Loading…
Reported covered position: Special Asst. to the President for Leg. Affairs (2009-2011); Chief of Staff, Sen. Sherrod Brown (2007-2009); Office of Leg & Intergovernmental Affairs, FCC (1999-2001)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues relating to Part D pricing reform; Issues relating to Part B pricing reform; S. 2543 - The Prescription Drug Price Reduction Act; H.R. 3 - Lower Drug Costs Now Act of 2019; Part B home infusion; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2021 · first_quarter · Q1
Issues relating to Part D pricing reform; Issues relating to Part B pricing reform; S. 2543 - The Prescription Drug Price Reduction Act; H.R. 3 - Lower Drug Costs Now Act of 2019; Part B home infusion; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Issues relating to Part D pricing reform; Issues relating to Part B pricing reform; S. 2543 - The Prescription Drug Price Reduction Act; H.R. 3 - Lower Drug Costs Now Act of 2019; Part B home infusion; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues relating to Part D pricing reform; Issues relating to Part B pricing reform; S. 2543 - The Prescription Drug Price Reduction Act; H.R. 3 - Lower Drug Costs Now Act of 2019; Part B home infusion; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.